A recent meta-analysis suggests there may be no meaningful overall survival benefit from adding hormone therapy to early salvage postoperative radiotherapy (PORT) in patients with prostate cancer who ...
ADT reduces testosterone, crucial for prostate cancer cell growth, but causes side effects impacting quality of life. Cardiovascular risks, insulin resistance, and bone density loss are significant ...
The study published by Bastiaan M Privé and colleagues in The Lancet Oncology represents, to our knowledge, the first randomised phase 2 trial evaluating lutetium-177–PSMA-617 (177Lu-PSMA-617) in ...
CLEVELAND – Data from a new study published in NEJM Evidence shows promise for personalized use of short term ADT in men with predominantly intermediate-risk prostate cancer. The study involved ...
—As more men are cured of prostate cancer, or are long-term survivors, the challenges of survivorship are in the spotlight. Improved screening practices, earlier detection, and better therapies have ...
Efficacy of rezvilutamide in preventing the flare phenomenon induced by GnRH agonists in newly diagnosed metastatic hormone-sensitive prostate cancer: An exploratory multicenter randomized controlled ...
Zoledronic acid reduced fracture risk by 27% in men with metastatic prostate cancer receiving ADT in the STAMPEDE trial. Patients with non-metastatic disease showed no significant fracture benefit ...
Xtandi addition to ADT and radiation did not significantly improve MFS in the overall high-risk prostate cancer population. Patients with clinical N1 disease showed improved five-year MFS with Xtandi, ...
SOLACE: A phase 1 pharmacokinetic, dosimetry, safety, and dose optimization study for a single dose of 153Sm-DOTMP to treat metastatic bone pain. This is an ASCO Meeting Abstract from the 2026 ASCO ...
Cribriform-positive morphology was associated with a 3.6-fold higher risk for metastasis in patients with prostate cancer, and radiotherapy with neoadjuvant androgen deprivation therapy (ADT) was ...
Morning Overview on MSN
Trial: Estradiol patches match injections for prostate cancer care
A randomized phase III trial run out of the United Kingdom has found that estradiol skin patches suppress testosterone as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results